Bioceltix (WAR:BCX) Total Equity: zł67.59 Mil (As of Mar. 2026)


WAR:BCX Bioceltix SA WAR:BCX
21 GF Score
Price zł90.40
! 1 Warning Sign
View Full Analysis

What is Bioceltix Total Equity?

Bioceltix WAR:BCX -0.44% 21 Total Equity is zł67.59 Mil as of Mar. 2026. GuruFocus rates WAR:BCX with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Bioceltix's total equity for the quarter that ended in Mar. 2026 was zł67.59 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bioceltix Total Equity Historical Data

* Premium members only.

The historical data trend for Bioceltix's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioceltix Total Equity Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 6.00 5.15 10.47 38.78 73.28

Bioceltix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.62 31.39 27.00 73.28 67.59
WAR:BCX
21GF Score
Bioceltix SA WAR:BCX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioceltix Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bioceltix's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=75.632-2.355
=73.28

Bioceltix's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=70.614-3.024
=67.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of zł67.59 Mil mean?
Bioceltix (WAR:BCX) has a Total Equity of zł67.59 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Bioceltix and its competitors.
Is Bioceltix's Total Equity too high?
Bioceltix's current Total Equity is zł67.59 Mil. Overall, Bioceltix has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Bioceltix's Total Equity compare to VRTX and REGN?
Bioceltix's Total Equity of zł67.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Bioceltix and its competitors. Bioceltix's current Total Equity is zł67.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioceltix stock overvalued right now?
Bioceltix (WAR:BCX) has a current Total Equity of zł67.59 Mil. The current Total Equity is zł67.59 Mil. Bioceltix's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Bioceltix (WAR:BCX), the current Total Equity is zł67.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioceltix Business Description

Address Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
21GF Score

Get the complete analysis for WAR:BCX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł90.40
Price